Cytori, Astellas in regenerative cell deal

Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA) granted Astellas Pharma Inc. (Tokyo:4503) a two-year right of first refusal to form a partnership for the development of Cytori's adipose-derived regenerative cells (ADRCs) to treat liver disease. Astellas will purchase about 1.4 million shares of Cytori stock at $7 per share, or about $10 million. The price is a 35% premium to Cytori's close of $5.20 on Monday, before the deal was announced. ...